Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04912050 · ClinicalTrials.gov registry record
EXtension of Tablo TrEatmeNt Duration Registry
A clinical trial, sponsored by Outset Medical.
- Completed
- Registry status
- 33
- Enrollment target
NCT04912050: Completed study, sponsored by Outset Medical.
NCT04912050 is a clinical trial that has completed, run by Outset Medical. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04912050 has completed, sponsored by Outset Medical.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
Observational, retrospective and prospective, multicenter, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy \> 12 hours.
Primary Outcome
Percentage of treatments achieving prescribed dialysis treatment time ≤ 10%
Interventions
- DEVICE Tablo Hemodialysis System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2022-05-31 |
What the finished NCT04912050 record still lists
NCT04912050 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Tablo Hemodialysis System is the first listed.
NCT04912050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04912050 about?
NCT04912050 is a clinical study titled "EXtension of Tablo TrEatmeNt Duration Registry". Observational, retrospective and prospective, multicenter, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy \> 12 hours.
What is the current status of trial NCT04912050?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2021-05-25. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT04912050?
The interventions under investigation include: Tablo Hemodialysis System (DEVICE).
Who is sponsoring clinical trial NCT04912050?
This trial is sponsored by Outset Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI